US 11,866,417 B2
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
Jerry Lee Atwood, Columbia, MO (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Oct. 1, 2020, as Appl. No. 17/061,473.
Application 17/061,473 is a continuation of application No. 16/670,801, filed on Oct. 31, 2019, granted, now 10,829,472.
Application 16/670,801 is a continuation of application No. 16/124,057, filed on Sep. 6, 2018, granted, now 10,487,069, issued on Nov. 26, 2019.
Application 16/124,057 is a continuation of application No. 15/849,324, filed on Dec. 20, 2017, granted, now 10,093,648, issued on Oct. 9, 2018.
Claims priority of provisional application 62/562,302, filed on Sep. 22, 2017.
Prior Publication US 2021/0024488 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01)
CPC C07D 401/04 (2013.01) [C07B 2200/13 (2013.01)] 10 Claims
 
1. A pharmaceutical composition comprising a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, wherein the hemihydrate has an X-ray powder diffraction pattern comprising peaks at 12.0, 17.2, and 25.6 degrees 2θ±0.2 degrees 2θ.